Katharine Hsu

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component
    K C Hsu
    Adult Allogeneic Blood and Marrow Transplantation Service, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Tissue Antigens 69:42-5. 2007
  2. ncbi KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy
    Katharine C Hsu
    Adult Allogeneic Bone Marrow Transplantation Service, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 12:828-36. 2006
  3. ncbi Natural killer cell receptors: regulating innate immune responses to hematologic malignancy
    Katharine C Hsu
    Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Semin Hematol 42:91-103. 2005
  4. ncbi Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
    Katharine C Hsu
    Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Blood 105:4878-84. 2005
  5. ncbi Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
  6. ncbi KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
  7. ncbi Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
  8. ncbi Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation
    Bo Dupont
    Immunology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Curr Opin Immunol 16:634-43. 2004
  9. ncbi Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation
    Junli Yu
    Immunology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 113:3875-84. 2009
  10. ncbi Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands
    Junli Yu
    Immunology Program, Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 179:5977-89. 2007

Research Grants

  1. NK Receptors and Bone Marrow Transplant Outcome
    Katharine Hsu; Fiscal Year: 2007
  2. NK Tolerance and Hematopoietic Cell Transplantation
    Katharine C Hsu; Fiscal Year: 2010
  3. NK Tolerance and Hematopoietic Cell Transplantation
    Katharine C Hsu; Fiscal Year: 2011

Collaborators

Detail Information

Publications20

  1. ncbi Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component
    K C Hsu
    Adult Allogeneic Blood and Marrow Transplantation Service, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Tissue Antigens 69:42-5. 2007
    ..KIR genotyping for unrelated donors and recipients will clarify the role of these receptors in transplant outcome...
  2. ncbi KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy
    Katharine C Hsu
    Adult Allogeneic Bone Marrow Transplantation Service, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 12:828-36. 2006
    ..This effect was not observed in HLA-identical unrelated transplants...
  3. ncbi Natural killer cell receptors: regulating innate immune responses to hematologic malignancy
    Katharine C Hsu
    Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Semin Hematol 42:91-103. 2005
    ....
  4. ncbi Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
    Katharine C Hsu
    Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Blood 105:4878-84. 2005
    ....
  5. ncbi Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  6. ncbi KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
    ..We hypothesized that patients with a "missing ligand" KIR-HLA compound genotype may uniquely benefit from autologous hematopoietic stem cell transplantation (HSCT)...
  7. ncbi Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
    ....
  8. ncbi Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation
    Bo Dupont
    Immunology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Curr Opin Immunol 16:634-43. 2004
    ..Therefore, the clinical benefits conferred by 'missing KIR ligand' might not be limited only to HLA mismatched donor-recipient combinations but may be applicable also to HLA identical transplants and even autologous HCT...
  9. ncbi Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation
    Junli Yu
    Immunology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 113:3875-84. 2009
    ....
  10. ncbi Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands
    Junli Yu
    Immunology Program, Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 179:5977-89. 2007
    ..These findings have important implications for the resting NK response to viral pathogens and malignancy, for donor selection in allogeneic hemopoietic cell transplantation, and for models of NK tolerance...
  11. ncbi KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro
    Joseph H Chewning
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 179:854-68. 2007
    ..This study also provides support for the concept that incompatibility for the HLA-KIR ligand groups C1, C2, and Bw4 dominates NK alloactivation in vitro...
  12. ncbi TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation
    Sandra Kesh
    Department of Medicine, Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 9, New York, NY 10021, USA
    Ann N Y Acad Sci 1062:95-103. 2005
    ..13 to 1.50; P < .001). Further analyses using a prospective cohort may enable us to identify TLR polymorphisms associated with the susceptibility to IA within a defined interval among immunocompromised patients...
  13. ncbi The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism
    Katharine C Hsu
    Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Immunol Rev 190:40-52. 2002
    ..Recent application of immunogenetic analysis of KIR genes in patient populations implicates these genes as important genetic disease susceptibility factors...
  14. ncbi Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets
    Katharine C Hsu
    Immunology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 169:5118-29. 2002
    ..Additional rare haplotypes can be identified, and may have arisen by gene duplication, intergenic recombination, or deletions...
  15. ncbi Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
    Joseph H Chewning
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:1313-23. 2007
    ....
  16. ncbi Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 115:3162-5. 2010
    ..Selection of donors with KIR3DS1 may decrease acute GVHD without compromising relapse-free survival, separating the graft-versus-tumor effect from unwanted GVHD...
  17. ncbi HLA alleles determine differences in human natural killer cell responsiveness and potency
    Sungjin Kim
    Howard Hughes Medical Institute, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Proc Natl Acad Sci U S A 105:3053-8. 2008
    ....
  18. ncbi Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002
    Steven G E Marsh
    Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Immunogenetics 55:220-6. 2003
  19. ncbi Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002
    Steven G E Marsh
    Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, London, United Kingdom
    Hum Immunol 64:648-54. 2003
  20. ncbi [Killer Ig-like receptor gene content diversity and haplotype analysis in Chinese Han population in Shanghai]
    Lei Zhang
    Shanghai Second Medical University, Shanghai Institute of Immunology, Shanghai, 200025 PR China
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20:396-9. 2003
    ..CONCLUSION: These findings suggest that there are distinctive frequencies of KIR gene content, haplotype as well as genotype in Chinese Han population in Shanghai area...

Research Grants6

  1. NK Receptors and Bone Marrow Transplant Outcome
    Katharine Hsu; Fiscal Year: 2007
    ..Dr. Hsu intends to develop a career as an independent investigator in the field of NK cell immunogenetics and allogeneic hematopoietic stem cell transplantation. ..
  2. NK Tolerance and Hematopoietic Cell Transplantation
    Katharine C Hsu; Fiscal Year: 2010
    ..Elucidating how NK cells achieve functional competence not only has implications for NK alloreactivity in the transplant setting, but also for judicious application of NK cells as adoptive cellular therapy for malignancies. ..
  3. NK Tolerance and Hematopoietic Cell Transplantation
    Katharine C Hsu; Fiscal Year: 2011
    ..Elucidating how NK cells achieve functional competence not only has implications for NK alloreactivity in the transplant setting, but also for judicious application of NK cells as adoptive cellular therapy for malignancies. ..